toggle menu

Sourcing & Management of Health Products

Information Notice

The aim of these notices is to provide guidance and advise on how to operationalize in practical terms the consequences of a quality or a safety issue related to a product which has been procured with Global Fund funds. The initial information, which should be stated in the notice, originates from the manufacturer of health products in question and/or confirmed by stringent regulatory mechanisms.

  • Quality Assurance Information Notice 2017-01: Voluntary Recall Initiated by Lupin for Isoniazid Tablets BP 100mg, Batches No A301856, A302231, A302408
    download in English | Español | Français
  • Quality Assurance Information Notice 2016-04: Remedica Product: Sulfadoxine / Pyrimethamine, 500/25 mg, Tablets – Eligibility Reinstated for Procurement with Global Fund Funds
    download in English
  • Quality Assurance Information Notice 2016-03: Hetero Labs Product: Efavirenz, Lamivudine, and Tenofovir, 600/300/300 mg Tablets – No Longer Eligible for Procurement with Global Fund Funds
    download in English | Español | Français
  • Quality Assurance Information Notice 2016-02: Recommendations Regarding the Procurement and the Distribution of Finished Pharmaceutical Products Using Active Pharmaceutical Ingredients Manufactured at IPCA Ratlam Manufacturing Site
    download in English | Español | Français
  • Quality Assurance Information Notice 2016-01: Recommendations Following WHO PQP Suspension of all the Prequalified Products Manufactured by Svizera Labs Private Limited
    download in English
We are using cookies to enhance the user experience on this website. By continuing on this website, you accept the use of cookies.